Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
Last 10 Buy Signals
Date |
Signal |
@ |
SNY | May 3 - 15:52 | $49.03 |
MANH | May 3 - 15:52 | $210.90 |
ARCC | May 3 - 15:53 | $20.61 |
BPMC | May 3 - 15:52 | $106.98 |
IDCC | May 3 - 15:51 | $103.67 |
DOX | May 3 - 15:51 | $83.86 |
PCAR | May 3 - 15:51 | $104.52 |
SOXX | May 3 - 15:50 | $215.71 |
TMUS | May 3 - 15:50 | $164.69 |
RMBS | May 3 - 15:50 | $55.89 |